A case of type 1 diabetes onset and recurrence of graves' disease during pegylated interferon-alpha plus ribavirin treatment for chronic hepatitis C

Internal Medicine

Volumn 49, Issue 18, 2010, Pages 1987-1990

  Fujioka, Takahiro ^a   Honda, Munehiro ^a   Yoshizaki, Tomoyuki ^a   Ogawa, Momoko ^a   Matsuno, Hisako ^a   Shimokawa, Koutaro ^b   Koyama, Kazunori ^c  

^a Mishuku Hospital   (Japan)

^b Yutenji Naika Clinic   (Japan)

^c International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

Autoimmune polyglandular syndrome; Basedows' disease; HLA; TSH receptor antibodies

Indexed keywords

GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; LIOTHYRONINE; PEGINTERFERON ALPHA; RIBAVIRIN; THIAMAZOLE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; VIRUS RNA;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GRAVES DISEASE; HEART PALPITATION; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE; KETOACIDOSIS; LABORATORY TEST; MALAISE; POLYURIA; RECURRENT DISEASE; SIDE EFFECT; THIRST; THYROID FUNCTION TEST; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; GRAVES DISEASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MIDDLE AGED; POLYENDOCRINOPATHIES, AUTOIMMUNE; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77957940776     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3831     Document Type: Article

References (22)

1. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321: 1506-1510, 1989.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
3. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 10: 115-150, 1994.
4. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002-1009, 2002.
5. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 26 (Suppl 1): 112S-121S, 1997.
6. Nagayama Y, Ohta K, Tsuruta M, et al. Exacerbation of thyroid autoimmunity by interferon aatreatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J 41: 565-572, 1994.
7. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 43: 661-672, 2006.
8. Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 47: 306-320, 2008.
9. Saji M, Moriarty J, Ban T, Singer DS, Kohn LD. Major histocompatibility complex class I gene expression in rat thyroid cells is regulated by hormones, methimazole, and iodide as well as interferon. J Clin Endocrinol Metab 75: 871-878, 1992.
10. Farrar JD, Murphy KM. Type 1 interferons and T helper development. Immunol Today 21: 484-489, 2000.
11. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112: 1017-1021, 1997.
12. Land KJ, Moll JS, Kaplan MH, Seetharamaiah GS. Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves' hyperthyroidism. Endocrinology 145: 3724-3730, 2004.
13. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves' - like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 170: 3522-3527, 2003.
14. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24: 38-47, 1996.
15. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25: 283-291, 1996.
16. Pujol-Borrell R, Todd I, Doshi M, et al. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 326: 304-306, 1987.
17. Foulis AK, Farquharson MA, Meager A. Immunoreactive alphainterferon in insulin-secreting uucells in type 1 diabetes mellitus. Lancet 2: 1423-1427, 1987.
18. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type 1 diabetes by interferon-M transgenic mice. Science 260: 1942-1946, 1993.
19. Eisembarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 350: 2068-2079, 2004.
20. Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon w-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract 86: e19-e21, 2009.
21. Hashimoto K, Maruyama H, Nishiyama M, et al. Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. Horm Res 64: 253-260, 2005.
22. Nakanishi K, Kobayashi T, Murase T, et al. Assoication of HLAA24 with complete w-cell destruction in IDDM. Diabetes 42: 1086-1093, 1993.